Skip to content
Homepage
Author:
NORTHWEST BIOTHERAPEUTICS, INC.
Posted Date:
August 6, 2026
Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company
NORTHWEST BIOTHERAPEUTICS, INC.
August 6, 2026
Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
NORTHWEST BIOTHERAPEUTICS, INC.
July 8, 2026
Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
NORTHWEST BIOTHERAPEUTICS, INC.
July 2, 2026
Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform
NORTHWEST BIOTHERAPEUTICS, INC.
April 30, 2026
Northwest Biotherapeutics Announces Establishment Of the Company’s Own Dedicated Leukapheresis Clinic
NORTHWEST BIOTHERAPEUTICS, INC.
April 21, 2026
